Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more

Recent & Breaking News (NDAQ:CLDX)

Celldex Therapeutics Announces Publication of Preliminary Data from the Phase 2 ReACT Study to be Presented at the 18th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)

Globe Newswire November 11, 2013

InvestorsGuru.com 44 Filtered Mid-Day Market Movers Recap

Investors Guru November 10, 2013

Celldex Reports Third Quarter 2013 Financial Results

Globe Newswire November 8, 2013

Celldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study

Globe Newswire November 7, 2013

ACAS, CLDX, GEVO and GPOR added to NASDAQ Active Stock Watch List at EPR

Accesswire November 6, 2013

Celldex Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings

Globe Newswire October 21, 2013

TSLA, HIMX, AGEN and CLDX added to Nasdaq Active Stock Watch List at EPR

Accesswire October 9, 2013

Cellular Biomedicine Has Multiple Near-Term Catalysts

Accesswire October 3, 2013

Celldex Therapeutics Announces Upcoming Presentation at the Leerink Swann Rare Disease Roundtable

Globe Newswire September 26, 2013

FSLR, LINE, GERN and CLDX added to NASDAQ Active Stock Watch List at EPR

Accesswire September 24, 2013

InvestorsGuru.com 41 Filtered Mid-Day Market Movers Recap

Investors Guru September 22, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ALXN, AMGN, CBST and CLDX

Accesswire September 6, 2013

Celldex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma

Globe Newswire August 12, 2013

Celldex Reports Second Quarter 2013 Financial Results

Globe Newswire August 6, 2013

Celldex Therapeutics Announces Issuance of Seminal Patent for CD27 Agonists

Globe Newswire July 10, 2013

InvestorsGuru.com 19 Filtered Mid-Day Market Movers Recap

Investors Guru July 6, 2013

Positive Data, Lease Agreements, and Product Launches Strengthen Portfolio - Research Report on Celldex, Teva, Health Management, Perrigo, and Alnylam

PR Newswire July 5, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ARIA, ARNA, CLDX and HALO

Accesswire July 2, 2013

Celldex Therapeutics Initiates Pilot Study in Dense Deposit Disease

Globe Newswire July 1, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ACAD, ACHN, CLDX and KERX

Accesswire June 24, 2013